We found that high expression of our TGF-β/Smad3 tumor-suppressor signature was associated with good outcome only in patients with ER+ tumors, suggesting that TGF-β plays a particularly important role in limiting progression of this breast cancer subtype. This evidence concerns the gene SMAD3 and breast cancer.